Atlas Trials

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Clinical trial NCT04053972 · UNKNOWN

Trial details

NCT number
NCT04053972
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2018-01-31
Primary completion
2022-12-31
Enrollment
377

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.